Early modifications of circulating microRNAs levels in metastatic colorectal cancer patients treated with regorafenib

Autor: Schirripa M1, Borelli B2, D'Aurizio R3, Lubrano S4, 5, Cremolini C2, Zucchelli G2, Antoniotti C2, Marmorino F2, Prete AA1, 6, Murgioni S1, Bergamo F1, Zagonel V1, Tuccoli A4, Marranci A4, Rizzo M4, Tedeschi L4, Magnoni L7, Falcone A2, Loupakis F1, Poliseno L4

Publikováno v: Pharmacogenomics journal (Online) (2019). doi:10.1038/s41397-019-0075-3
info:cnr-pdr/source/autori:Schirripa M1, Borelli B2, D'Aurizio R3, Lubrano S4,5, Cremolini C2, Zucchelli G2, Antoniotti C2, Marmorino F2, Prete AA1,6, Murgioni S1, Bergamo F1, Zagonel V1, Tuccoli A4,5, Marranci A4,5, Rizzo M4, Tedeschi L4, Magnoni L7, Falcone A2, Loupakis F1, Poliseno L4,8./titolo:Early modifications of circulating microRNAs levels in metastatic colorectal cancer patients treated with regorafenib/doi:10.1038%2Fs41397-019-0075-3/rivista:Pharmacogenomics journal (Online)/anno:2019/pagina_da:/pagina_a:/intervallo_pagine:/volume

Biomarkers able to improve the cost/benefit ratio are urgently needed for metastatic colorectal cancer patients that are eligible to receive regorafenib. Here, we measured plasma levels of ten circulating microRNAs (c-miRNAs) and we investigated thei

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::278531ee2d4f05c999a9c564719d84d4
http://hdl.handle.net/11568/990700